At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 156 enrolled
Drug / intervention
Tanezumabdrug
Likely dose
Tanezumab 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY
In Brief
A Phase 3 clinical trial evaluating Tanezumab for Bone Metastasis and Cancer Pain. Completed, enrolled 156 participants across 89 sites in 16 countries.
Detailed Summary
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Metastasis, Cancer Pain
CountriesArgentina, Australia, Austria, Brazil, Chile, China, Czechia, Hungary, Israel, Japan, Poland, Romania, Slovakia, South Korea, Spain, United Kingdom
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedNov 2015
Primary CompletionSep 2020
Study CompletionJun 2021
TodayJul 2026
First PostedNov 20, 2015
Enrollment StartOct 28, 2015
Primary CompletionSep 17, 2020
Study CompletionJun 25, 2021
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 10.6 years ago
Interventions
Tanezumabdrug
Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.